Bayer Diagnostics will be facilitating a lunchtime seminar on B-type natriuretic peptide (BNP) at the IBMS Meeting on Tuesday 30 September 2003
Bayer Diagnostics will be facilitating a lunchtime seminar on B-type natriuretic peptide (BNP) at the IBMS Meeting on Tuesday 30 September 2003.
BNP has recently been added to the range of cardiovascular assays available for use on Bayer's Advia Centaur immunoassay system - one of only two automated BNP methods to have gained approval from the FDA.
Roy Sherwood of King's College Hospital, London, will discuss what BNP is and its use as an additional tool to enhance the diagnosis of congestive heart failure.
In particular, his talk will focus on how BNP fits into the diagnostic regime for heart failure and how this will impact on current National Service Framework and Nice guidelines for heart failure diagnosis and management.
In addition, the discussion will cover the use of BNP in assessing the severity of disease, its value in prognosis and the emerging application of the assay as a tool for monitoring the effectiveness of drug therapy.
